公开(公告)号：US12129301B2

公开(公告)日：2024-10-29

申请号：US17932450

申请日：2022-09-15

Applicant: National University Corporation Tokai National Higher Education and Research System

Inventor： Mitsuro Kanda

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/04 ,  C12N15/113 ,  G01N33/574

CPC classification number: C07K16/286 ,  A61P35/04 ,  C12N15/1138 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57438 ,  G01N33/57446 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/76 ,  C12N2310/141

Abstract: From gene expression analysis with a long-term recurrence-free group and a recurrence metastasis group of stomach cancer, CHRNB2 and NPTXR were identified as drug discovery targets. Tumor growth was successfully inhibited by an antibody medicine or a nucleic acid medicine targeting CHRNB2 or NPTXR. Furthermore, a polyclonal antibody and a monoclonal antibody linking to CHRNB2 or NPTXR are provided. Since these receptor molecules are novel molecular targets, treatment of cases which the existing therapeutic drugs have no effect on is made possible.

公开(公告)号：US20240336695A1

公开(公告)日：2024-10-10

申请号：US18640480

申请日：2024-04-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Bryan C. BARNHART ,  Brigitte DEVAUX ,  Aaron P. YAMNIUK ,  Shannon L. OKADA ,  Brenda L. STEVENS

IPC: C07K16/28 ,  A61K39/00 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04

CPC classification number: C07K16/2878 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

公开(公告)号：US12110334B2

公开(公告)日：2024-10-08

申请号：US18153277

申请日：2023-01-11

Applicant: The Regents of the University of California

Inventor： Stephen L. Nishimura ,  Jianlong Lou ,  James D. Marks ,  Jody L. Baron ,  Yifan Cheng ,  Shenping Wu ,  Anthony Cormier ,  Naoki Takasaka

IPC: G01N33/53 ,  A61P1/04 ,  A61P31/20 ,  A61P35/04 ,  A61P37/04 ,  C07K14/705 ,  C07K16/00 ,  C07K16/22 ,  C07K16/28 ,  C07K16/46 ,  G01N33/563 ,  A61K39/00

CPC classification number: C07K16/2839 ,  A61P1/04 ,  A61P31/20 ,  A61P35/04 ,  A61P37/04 ,  C07K14/705 ,  C07K16/22 ,  G01N33/563 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: New antibodies and methods of use are described.

公开(公告)号：US12109193B2

公开(公告)日：2024-10-08

申请号：US17260745

申请日：2019-07-29

Applicant: Loxo Oncology, Inc.

Inventor： Barbara J. Brandhuber ,  Lauren T. Brent ,  Charles Todd Eary ,  Andrew Kenna ,  Firas Khan ,  Vivian F. H. Renshaw ,  Stacey Renee Spencer

IPC: A61K31/415 ,  A61K9/00 ,  A61K9/20 ,  A61K31/635 ,  A61P35/04 ,  C07K16/28

CPC classification number: A61K31/415 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/635 ,  A61P35/04 ,  C07K16/2887 ,  C07B2200/13

Abstract: A spray-dried dispersions and pharmaceutical composition of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the spray-dried dispersion and pharmaceutical composition in the treatment of cancer and autoimmune and inflammatory diseases are disclosed. Also provided are crystalline forms of (S)-5-amino-3-(4-((5-fluoro-2-methoxy-benzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide also useful in the treatment of cancer and autoimmune and inflammatory diseases.

公开(公告)号：US12098146B2

公开(公告)日：2024-09-24

申请号：US16751803

申请日：2020-01-24

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： Iwona Wrona ,  Kerem Ozboya ,  Matthew Lucas ,  Bhaumik Pandya ,  Bertrand Le Bourdonnec

IPC: C07D413/04 ,  A61K31/166 ,  A61K31/175 ,  A61K31/436 ,  A61K31/4439 ,  A61K31/453 ,  A61K31/4545 ,  A61K31/475 ,  A61K31/495 ,  A61K31/497 ,  A61K31/501 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  A61P35/04 ,  C07D237/22 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61P35/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D413/04 ,  C07D417/14 ,  A61K31/495

Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

公开(公告)号：US20240308986A1

公开(公告)日：2024-09-19

申请号：US18661960

申请日：2024-05-13

Applicant: RADIUS PHARMACEUTICALS, INC.

Inventor： Chris MILLER

IPC: C07D403/10 ,  A61P35/04 ,  C07D209/30 ,  C07D333/64 ,  C07D409/12 ,  C07D487/04 ,  C07D495/04

CPC classification number: C07D403/10 ,  A61P35/04 ,  C07D209/30 ,  C07D333/64 ,  C07D409/12 ,  C07D487/04 ,  C07D495/04

Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US20240299567A1

公开(公告)日：2024-09-12

申请号：US18272107

申请日：2022-01-14

Applicant: Ming-Che SHIH ,  Academia Sinica

Inventor： Che MA ,  Wen-Hwa LEE ,  Tracer YONG

IPC: A61K47/64 ,  A61K39/00 ,  A61P35/04 ,  C07K14/715

CPC classification number: A61K47/646 ,  A61K47/6415 ,  A61P35/04 ,  C07K14/7155 ,  A61K39/00 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/645 ,  C07K2319/40

Abstract: Disclosed herein is a recombinant polypeptide comprising 1 to 20 copies of an IL-17RB inactivation site (IRIS) sequence. Also disclosed herein is the use of the recombinant polypeptide in the preparation of a conjugate for the treatment of cancers.

公开(公告)号：US20240285686A1

公开(公告)日：2024-08-29

申请号：US18571575

申请日：2022-06-15

Applicant: WEST CHINA HOSPITAL, SICHUAN UNIVERSITY

Inventor： Xudong ZHAO ,  Bin SUN

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/04 ,  C07K14/725 ,  C12N5/0783 ,  C12N5/10 ,  C12N9/64 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464476 ,  A61P35/04 ,  C07K14/7051 ,  C12N5/0636 ,  C12N5/10 ,  C12N9/6467 ,  C12N15/86 ,  A61K2239/15 ,  A61K2239/17 ,  A61K2239/21 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00 ,  C12N2740/15043 ,  C12Y304/21079

Abstract: A preparation and an application of a chimeric antigen receptor immune cell constructed on the basis of granzyme B are provided, including, a granzyme B (GrB)-based modified chimeric antigen receptor (CAR), the CAR containing an extracellular binding domain, and the extracellular binding domain being capable of specifically targeting heat shock proteins. The CAR immune cell acts by means of binding of a ligand and a receptor, and has relatively high targeting specificity and relatively better safety.

公开(公告)号：US20240285659A1

公开(公告)日：2024-08-29

申请号：US18412414

申请日：2024-01-12

Applicant: Beth Israel Deaconess Medical Center, Inc.

Inventor： Jeffrey I. ZWICKER ,  Bruce FURIE ,  Jack Davis STOPA ,  Robert FLAUMENHAFT

IPC: A61K31/7048 ,  A61K31/352 ,  A61K31/375 ,  A61K31/45 ,  A61K31/519 ,  A61P35/04

CPC classification number: A61K31/7048 ,  A61K31/352 ,  A61K31/375 ,  A61K31/45 ,  A61K31/519 ,  A61P35/04

Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.

公开(公告)号：US20240279305A1

公开(公告)日：2024-08-22

申请号：US18637627

申请日：2024-04-17

Applicant: Alector LLC

Inventor： Spencer Liang ,  Samuel Nalle ,  Jeonghoon Sun ,  Rashmi Bankoti ,  Hua Long

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  A61P35/04 ,  C07K16/28

CPC classification number: C07K14/70503 ,  A61K38/1774 ,  A61K45/06 ,  A61P35/00 ,  A61P35/04 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/545 ,  C07K2317/76 ,  C07K2319/30

Abstract: The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.